The FDA approves Bristol Myers' (BMY) Zeposia for the treatment of adults with relapsing forms of multiple sclerosis....

Supply-chain disruptions due to coronavirus outbreak may hurt biotech companies' first-quarter earnings. However, those making treatments/vaccines may make huge profits if their products get approval....

To keep the diabetes community informed about important developments from the COVID-19 crisis, Eli Lilly and Company (NYSE: LLY) today is providing updates related to insulin supply and affordability:...

Lilly and Bristol are the biggest drugmakers yet to announce clinical trial delays in the face of the pandemic that has killed over 16,000 people worldwide, after several small biotech companies said last week that they would be pulling back on drug studies. The moves are not related to clinical trials...

Kaiser Permanente executive Kathryn Beiser will join healthcare giant Eli Lilly and Company as vice president of global communications effective April 6 as the company prepares to navigate the front lines of developing a possible coronavirus treatment. Beiser will oversee all aspects of the Indianapolis-based company's corporate communications strategy, including internal and external corporate communications, media relations, crisis management, executive communications, digital and social media and corporate brand and reputation management. Lilly (NYSE: LLY) said March 13 it hopes to start testing a treatment for COVID-19 it is co-developing with privately held AbCellera Biologics in the coming months, CNBC reported....

Shares of Eli Lilly and Co. were down 2% in trading on Monday. The drugmaker has announced Monday morning that it will delay the start of most new clinical studies and is pausing enrollment of participants in ongoing trials due to the COVID-19 pandemic. Trials that have already enrolled patients will continue, the company said. "We hope to ease the burden on participating health care facilities and allow physicians to focus more of their efforts on combatting COVID-19," Lilly chief medical officer Tim Garnett said in a statement. Lilly's stock has dropped 8% year-to-date, while the S&P 500 is down 28%....

Lilly's (LLY) label expansion application seeking approval of its type II diabetes medicine as a treatment for type I diabetes fails to get approval from the FDA....

The decision makes Lilly the biggest drugmaker to delay clinical trials in the face of the pandemic that has killed over 14,600 people worldwide. The move would "ease the burden on participating healthcare facilities and allow physicians to focus more of their efforts on combatting COVID-19,"...

Eli Lilly and Company (NYSE: LLY) today provided an update on the company's clinical trial activities in light of the COVID-19 pandemic. The company will delay most new study starts and pause enrollment in most ongoing studies. Lilly is continuing ongoing clinical trials for patients who are already...

Eli Lilly and Company (NYSE:LLY) will offer drive-through testing for SARS-CoV-2, the virus that causes COVID-19, to Indianapolis area health care workers beginning Monday, March 23, as a service to the community and in an effort to protect health care providers working on the front lines during this...